Carlsmed (CARL) Preferred Stock Liabilities (2024 - 2025)
Carlsmed posted quarterly Preferred Stock Liabilities of $65.4 million for Q2 2025, up 119.29% year-on-year from $29.8 million in Q2 2024, and up 119.29% on a QoQ basis from $29.8 million in Q1 2025.
Carlsmed (CARL) has 2 years of Preferred Stock Liabilities data on file, last reported at $65.4 million in Q2 2025.
- For the quarter ending Q2 2025, Preferred Stock Liabilities rose 119.29% year-over-year to $65.4 million; the trailing twelve-month figure through Jun 2025 stood at $65.4 million (up 119.29% YoY), and the FY2024 full-year result was $52.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2025 stood at $65.4 million, up from $29.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $65.4 million in Q2 2025 and bottomed at $29.8 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | - |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | - |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | - |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | 199.87 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | - |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | - |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | - |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | - |
| 10 | Carlsmed | 298.68 Mn | 201.48 Mn | 12.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 65.35 Mn |
| Mar 31, 2025 | 29.80 Mn |
| Dec 31, 2024 | 52.85 Mn |
| Sep 30, 2024 | 29.80 Mn |
| Jun 30, 2024 | 29.80 Mn |